Riitta Lassila

Quintiles, Inc. provides therapeutic services. It offers medical services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. The company was founded in 1982 and is headquartered in San Francisco, CA.

Insense Ltd. develops products for treatment of wounds and skin conditions. Its development activity is concentrated on dermatology products for both professional and consumer applications. The company was founded in 2001 by Paul James Davis and is headquartered in Bedford, the United Kingdom.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

Lallemand Finland Oy develops, manufactures and markets biological pesticides and growth promoters. It offers products and services to forestry, horticulture and amenity sectors. The company's products include Rotstop, Turf Mark Dye Tablet, Mycostop, Mycostop Mix, and GlioMix. Verdera was founded in 2002 and is headquartered in Espoo, Finland.

Encorium Group, Inc. is a clinical research organization which is engaged in the design and management of complex clinical trials for the pharmaceutical and biotechnology industries. It offers on a global basis broad range of clinical research and development services supporting Phase I through Phase IV clinical trials. The company's services include study protocol design, clinical trials management, global data management services, biostatistics, medical and regulatory affairs, quality assurance and compliance and medical report writing. The Encorium offers therapeutic areas such as vaccines, oncology, CNS/psychiatry, cardiovascular, dermatology, rheumatology, respiratory disorders and renal and urinary disorders. The company was founded on August 1, 1998 and is headquartered in Wayne, Pennsylvania.

Inveni Capital Oy is a venture capital investment firm with offices in Helsinki and Munich. The Finnish-German firm was founded in 2007. Their investors include the Finnish Industry Investment Ltd. as largest single investor, along with other private investors and funds as well as the University of Helsinki.

Diabetology Ltd. offers biopharmaceutical research and development services. It develops Capsulin and novel Axcess oral form of insulin for diabetics that incorporates absorption enhancers with unmodified bioactive in a convenient encapsulated form. The company was founded by Roger New and Glen Travers in 2002 and is headquartered in St. Helier, Jersey.

Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom.

Cupori Group Oy operates as a holding company with interests in manufactures and supplies copper plumbing installation tubes. It provides tubes for plumbing, refrigeration, medical gas, and industrial purposes. The company is headquartered in Espoo, Finland.

Onbone Oy develops medical casting and splinting materials for use in the fields of orthopaedics, traumatology and occupational therapy. The company was founded by Petro Antero Kirmo Lahtinen, Antti Pärssinen, Jari Juhani Salo, Matti Eino Olavi Vaheri, and Karri Airola on November 18, 2008 and is headquartered in Oulu, Finland.

EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France.

Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom.

Paion Deutschland GmbH engages in the development of pharmaceutical products. The company is headquartered in Aachen, Germany.

Midatech Ltd. engages in research and experimental development on biotechnology services. The company is headquartered in Abingdon, the United Kingdom.

Medtentia International Ltd. Oy is a holding company that develops solutions for mitral valve repair based on its proprietary helix ring concept. It is a medical technology company that creates solutions for cardiac interventions. It provides proprietary, helix-shaped products to address the unmet need in cardiac surgery. The company was founded by Dan Mogren and Olli U. Keränen in 2002 by Olli Keränen and is headquartered in Espoo, Finland.

Laurantis Pharma Oy engages in the development of pharmaceutical products. The company was founded in July 2008 and is headquartered in Turku, Finland.

Indcrea Oy provides consultancy services. The private company is based in Espoo, Finland.

ImevaX GmbH develops vaccines against pathogens of chronic infectious diseases, especially helicobacter pylori. It offers diagnostic and therapeutic methods for bacterial agents. The company was founded by Markus Gerhard in 2014 and is headquartered in Munich, Germany.

Aranda Pharma Ltd. engages in the research and development of novel small molecules to combat prostate cancer and neurodegenerative diseases. The company was founded by Anu Muona, Milla Koistinaho, Jari Koistinaho, and Gundars Goldsteins in September 2015 and is headquartered in Kuopio, Finland.

Rokote Laboratories Finland Oy is a Finnish vaccine development company established in 2020 with premises located in Kuopio and Helsinki. The private company aims to consolidate the use of new vaccine technology and is currently developing a second-generation coronavirus vaccine. The company's focus is on developing a COVID-19 vaccine, with clinical trials set to begin this year.